Introduction: Benign Prostate Hyperplasia (BPH) is a common disease in adult men and its incidence is age related. Attending to high prevalence of BPH in older men with renal insufficiency it is invaluable to take into consideration the relationship between these two clinical entities. The purpose of this study was to determine the incidence of renal failure associated with BPH, effect of TURP in the morbidity and mortality of patients with renal failure. The aims of this study are to study the prevalence of co-morbid factors in patients with Benign prostatic hyperplasia and non dialysis requiring renal insufficiency, Study of treatment outcome following  transurethral resection of prostate (TURP) with non dialysis requiring renal failure and to study of complications associated with TURP  in these patients.

Materials and Methods: This is a Prospective study conducted between JAN 2015 to AUG 2017 in Department of Urology, Government Kanyakumari Medical College, Nagercoil, Tamilnadu, India. This is a study of 40 cases of Benign prostatic hyperplasia in normal and in patients with non dialysis requiring renal failure who underwent TURP. The inclusion criteria being all patients with Non dialysis requiring Renal Dysfunction associated with BPH. The exclusion criteria being histologically proven malignant prostatomegaly and patients with end stage renal disease requiring hemodialysis.

Results and Conclusion: The incidence of renal failure associated with BPH in our study was about 12.5%. After excluding patients with prostatic malignancy, patients needing dialysis, the study group constituted 5%. There was no significant variation in preoperative and postoperative levels of serum sodium, potassium levels in patients with nondialysis requiring renal failure (S.creatinine less than 3), when compared to normal patients. Complications of TURP in patients who had nondialysis requiring renal failure, was on the higher side. Bleeding as a complication requiring blood transfusion was noted in 20% of patients compared to normal patients. But overall complication rate was not statistically significant. This can be attributed to either small sample size, improvement in instruments like continuous flow resectoscope, use of non hemolytic irrigation solutions can be a factor. The outcome following TURP was successful with restoration in normal renal function and normal voiding pattern in majority of patients and it was further noted that the successful outcome of TURP in these patients were influenced by various factors such as age, duration of symptoms, severity of lower urinary tract symptoms, severity of renal failure at the time of presentation. The size of Prostate gland had no correlation with the final outcome.

Keywords: Benign prostatic hyperplasia, Renal failure, Chronic kidney disease, Transurethral resection of prostate.

1. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology. 1991; 38(1 Suppl): p. 4-8.
2. Kumar R, Hill CM, McGeown MG. Acute renal failure in the elderly. Lancet. 1973 Jan; 1(7794): p. 90-91.
3. Wein A. campbell-walsh urology Wein AJ, editor.: elsevier; 2012.
4. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep; 132(3): p. 474-479.
5. Nielsen KK, Nordling J, Hald T. Critical review of the diagnosis of prostatic obstruction. Neurourol Urodyn. 1994; 13(3): p. 201- 217.
6. Abrams P. LUTS, BPH, BPE, BPO: A Plea for the Logical Use of Correct Terms. Rev Urol. 1999; 1(2): p. 65.
7. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003 Dec; 44(6): p. 637-649.
8. Wu Sl, Li Nc, Xiao Yx, Jin J, Qiu Sp, Ye Zq, et al. Natural history of benign prostate hyperplasia. Chin Med J (Engl). 2006 Dec; 119(24): p. 2085-2089.
9. Rule AD, Jacobson DJ, Roberts RO, Girman CJ, McGree ME, Lieber MM, et al. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int. 2005 Jun; 67(6): p. 2376-2382.
10. Ponholzer A, Temml C, Obermayr RP, Rauchenwald M, Madersbacher S. The association between lower urinary tract symptoms and renal function in men: a cross-sectional and 5-year longitudinal analysis. J Urol. 2006 Apr; 175(4): p. 1398-1402.
11. Hallan SI, Kwong D, Vikse BE, Stevens P. Use of a prostate symptom score to identify men at risk of future kidney failure: insights from the HUNT II Study. Am J Kidney Dis. 2010 Sep; 56(3): p. 477-485.
12. Yamasaki T, Naganuma T, Iguchi T, Kuroki Y, Kuwabara N, Takemoto Y, et al. Association between chronic kidney disease and small residual urine volumes in patients with benign prostatic hyperplasia. Nephrology (Carlton). 2011 Mar; 16(3): p. 335-339.
13. Hong SK, Lee ST, Jeong SJ, Byun SS, Hong YK, Park DS, et al. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2010 May; 105(10): p. 1424-1428.
14. Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl. 1996; 6: p. 67 -73.
15. Coroneos E, Assouad M, Krishnan B, Truong LD. Urinary obstruction causes irreversible renal failure by inducing chronic tubulointerstitial nephritis. Clin Nephrol. 1997 Aug; 48(2): p. 125-128.
16. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978 Jan; 15(4): p. 340-345.
17. Lin VK, Robertson JB, Lee IL, Zimmern PE, McConnell JD. Smooth muscle myosin heavy chains are developmentally regulated in the rabbit bladder. J Urol. 2000 Oct; 164(4): p. 1376-1380.
18. Schwinn DA. Adrenergic receptors: unique localization in human tissues. Adv Pharmacol. 1994; 31: p. 333-341.
19. Boesch ST, Dobler G, Ramoner R, Corvin S, Thurnher M, Bartsch G, et al. Effects of alpha1-adrenoceptor antagonists on cultured prostatic smooth muscle cells. Prostate Suppl. 2000; 9: p. 34-41.
20. Hassanzadeh K, Yavari-kia P, Ahmadi-Asrbadr Y, Nader-Abbasi F. Non-obstructive lower urinary tract symptoms versus prostate volume in benign prostatic hyperplasia. Pak J Biol Sci. 2010 Dec; 13(23): p. 1129-1134.
21. Hill AM, Philpott N, Kay JD, Smith JC, Fellows GJ, Sacks SH. Prevalence and outcome of renal impairment at prostatectomy. Br J Urol. 1993 Apr; 71(4): p. 464-468.
22. Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int. 2005 Jan; 95(1): p. 15-19.
23. Sacks SH, Aparicio SA, Bevan A, Oliver DO, Will EJ, Davison AM. Late renal failure due to prostatic outflow obstruction: a preventable disease. BMJ. 1989 Jan; 298(6667): p. 156-159
24. Styles RA, Ramsden PD, Neal DE. The outcome of prostatectomy on chronic retention of urine. J Urol. 1991 Oct; 146(4): p. 1029- 1033.
25. Prakash J, Saxena RK, Sharma OP, Usha. Spectrum of renal diseases in the elderly: single center experience from a developing country. Int Urol Nephrol. 2001; 33(2): p. 227-233.
26. Jones DA, Gilpin SA, Holden D, Dixon JS, O'Reilly PH, George NJ. Relationship between bladder morphology and long-term outcome of treatment in patients with high pressure chronic retention of urine. Br J Urol. 1991 Mar; 67(3): p. 280-285.
27. Gosling JA, Dixon JS. Structure of trabeculated detrusor smooth muscle in cases of prostatic hypertrophy. Urol Int. 1980; 35(5): p. 351-355.
28. Comiter CV, Sullivan MP, Schacterle RS, Cohen LH, Valla SV. Urodynamic risk factors for renal dysfunction in men with obstructive and nonobstructive voiding dysfunction. J Urol. 1997 Jul; 158(1): p. 181-185.
29. Jones SA, Ellis JR, Klegeris A, Greenfield SA. The relationship between visual stimulation, behaviour and continuous release of protein in the substantia nigra. Brain Res. 1991 Sep; 560(1-2): p. 163-166.
30. Ghose RR, Harindra V. Unrecognised high pressure chronic retention of urine presenting with systemic arterial hypertension. BMJ. 1989 Jun; 298(6688): p. 1626-1628.
31. Klahr S. Urinary tract obstruction. Semin Nephrol. 2001 Mar; 21(2): p. 133-145.
32. Gerber GS, Goldfischer ER, Karrison TG, Bales GT. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 1997 May; 49(5): p. 697-702.
33. Jacobsen SJ, Guess HA, Panser L, Girman CJ, Chute CG, Oesterling JE, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med. 1993 Jul; 2(7): p. 729-735.
34. Neal DE. Irreversible renal failure in men with outflow obstruction: is it a preventable disease? Postgrad Med J. 1990 Dec; 66(782): p. 996-999.
35. Tseng TY, Stoller ML. Obstructive uropathy. Clin Geriatr Med. 2009 Aug; 25(3): p. 437-443.
36. Cockett AT, Barry MJ, Holtgrewe HL, Sihelnick S, Williams R, McConnell J. Indications for treatment of benign prostatic hyperplasia. The American Urological Association Study. Cancer. 1992 Jul; 70(1 Suppl): p. 280-283.
37. HOLTGREWE HL, VALK WL. Factors influencing the mortality and morbidity of transurethral prostatectomy: a study of 2,015 cases. J Urol. 1962 Mar; 87: p. 450-459.
38. Melchior J, Valk WL, Foret JD, Mebust WK. Transurethral prostatectomy in the azotemic patient. J Urol. 1974 Nov; 112(5): p. 643-646.
39. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC, WCtAUA. Transurethral prostatectomy: immediate and postoper-ative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol, 141: 243-247, 1989. J Urol. 2002 Jan; 167(1): p. 5-9.
40. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin. 1994 Feb;(8): p. 1-17.
41. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin. 1994 Feb;(8): p. 1-17.
42. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998 Feb; 338(9): p. 557-563.
43. Barry MJ, Fowler JF, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov; 148(5): p. 1549--57; discussion 1564.
44. Hong SK, Oh JJ, Jeong SJ, Jeong CW, Kim IS, Park JM, et al. Prediction of outcomes after radical prostatectomy in patients diagnosed with prostate cancer of biopsy Gleason score ≥ 8 via contemporary multi (≥ 12)-core prostate biopsy. BJU Int. 2011 Jul; 108(2): p. 217-222.
45. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989 Feb; 141(2): p. 243-247.
46. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008 Mar; 101 Suppl 3: p. 17-21.
47. Koch WF, Debruyne FM,. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol. 1996 Jan; 155(1): p. 186-189.
48. Sutaria PM, Staskin DR. Hydronephrosis and renal deterioration in the elderly due to abnormalities of the lower urinary tract and ureterovesical junction. Int Urol Nephrol. 2000; 32(1): p. 119-126.
49. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O, Watanabe H. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J Urol. 1997 Feb; 157(2): p. 476-479.
50. Gabuev A, Oelke M. [Latest trends and recommendations on epidemiology, diagnosis, and treatment of benign prostatic hyperplasia (BPH)]. Aktuelle Urol. 2011 May; 42(3): p. 167-178.
51. Neal DE, Styles RA, Powell PH, Ramsden PD. Relationship between detrusor function and residual urine in men undergoing prostatectomy. Br J Urol. 1987 Dec; 60(6): p. 560-566.
52. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a communitybased population of healthy aging men. J Clin Epidemiol. 2001 Sep; 54(9): p. 935-944.
53. Emberton M, Andriole GL, , Djavan B, Hoefner K, , et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003 Feb; 61(2): p. 267-273.
54. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol. 1998 Jul; 160(1): p. 12--6; discussion 16-7.
55. Thomas AZ, Thomas AA, Conlon P, Hickey D, Little DM. Benign prostatic hyperplasia presenting with renal failure--what is the role for transurethral resection of the prostate (TURP)? Ir Med J. 2009 Feb; 102(2): p. 43-44.
56. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, mana-gement, and prevention. Eur Urol. 2006 Nov; 50(5): p. 969--79; discussion 980.
57. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol. 1999 Oct; 162(4): p. 1307-1310.
58. Wendt-Nordahl G, Häcker A, Reich O, Djavan B, Alken P, Michel MS. The Vista system: a new bipolar resection device for endourological procedures: comparison with conventional resectoscope. Eur Urol. 2004 Nov; 46(5): p. 586-590.
59. Schatzl G, Madersbacher S, Djavan B, Lang T, Marberger M. Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options. Eur Urol. 2000 Jun; 37(6): p. 695-701.
60. Berger AP, Wirtenberger W, Bektic J, Steiner H, Spranger R, Bartsch G, et al. Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications. J Urol. 2004 Jan; 171(1): p. 289-291.
61. McAfee JG, Singh A, O'Callaghan JP. Nuclear imaging supplementary to urography in obstructive uropathy. Radiology. 1980 Nov; 137(2): p. 487-496.
62. Green J, Vardy Y, Munichor M, Better OS. Extreme unilateral hydronephrosis with normal glomerular filtration rate: physiological studies in a case of obstructive uropathy. J Urol. 1986 Aug; 136(2): p. 361-365.
63. Hunter DJ, Berra-Unamuno A, Martin-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. J Urol. 1996 Jun; 155(6): p. 1965-1970.
64. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001 Dec; 58(6 Suppl 1): p. 5--16; discussion 16.
65. OLBRICH O, WOODFORD-WILLIAMS E, IRVINE RE, WEBSTER D. Renal function in prostatism. Lancet. 1957 Jun; 272(6983): p. 1322-1324.
66. Terris MK, Afzal N, Kabalin JN. Correlation of transrectal ultrasound measurements of prostate and transition zone size with symptom score, bother score, urinary flow rate, and post-void residual volume. Urology. 1998 Sep; 52(3): p. 462-466.
67. Camici M, Sagripanti A. [Uremic coagulopathy. Role of thrombin]. Minerva Urol Nefrol. 2000 Jun; 52(2): p. 67-72.
68. Christ GJ, Liebert M. Proceedings of the Baltimore smooth muscle meeting: identifying research frontiers and priorities for the lower urinary tract. J Urol. 2005 Apr; 173(4): p. 1406-1409.
69. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr; 12(5 Suppl): p. S122--S128.
70. Alp Ozgur Akdemir, Cetin Volkan Oztekin, Omer Gokhan Doluoglu. Effects of Transurethral resection of prostate on morbidity and mortality in patients with nondialysis- requiring renal insufficiency. Ther Adv Urol.2012 Apr; 4(2):51-56.

Selvakumar Soman

Department of Urology, Government Kanyakumari Medical College,

Nagercoil, Tamilnadu, India